Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) (OAIE)

of musculoskeletal lesions is worse than that of pulmonary lesions. This treatment failure has been partly overcome by the addition of ifosfamide and etoposide (IE). We have ever retrospectively

  • 0 views
  • 22 Apr, 2022
  • 1 location
Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma

Apatinib mesylate is a multitarget receptor tyrosine kinase inhibitor. This trial is to evaluate the efficacy and safety of apatinib mesylate combined with doxorubicin and ifosfamide in the

stromal tumor
leiomyosarcoma
angiosarcoma
undifferentiated pleomorphic sarcoma
ifosfamide
  • 0 views
  • 24 Nov, 2021
  • 1 location
Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma

of musculoskeletal lesions is worse than that of pulmonary lesions. This treatment failure has been partly overcome by the addition of ifosfamide and etoposide (IE). We have ever retrospectively

  • 0 views
  • 21 Jul, 2021
  • 2 locations
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

This phase II trial studies the side effects of nivolumab and to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma

  • 1 views
  • 12 Jul, 2022
  • 3 locations
The Combination of Sintilimab and AI (Doxorubicin ADM/Ifosfamide IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

This is a phase II trial to explore the feasibility of PD-1 immune check point inhibitor, sintilimab, in combination of stand of care chemotherapy in first-line treatment of selected soft tissue sarcoma.

soft tissue sarcoma
undifferentiated pleomorphic sarcoma
ifosfamide
cancer chemotherapy
neutrophil count
  • 0 views
  • 25 Jan, 2021
  • 1 location
Polatuzumab Vedotin Rituximab Ifosfamide Carboplatin and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell

  • 0 views
  • 10 Oct, 2021
  • 2 locations
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

Nearly half of patients with high-grade, localized soft tissue sarcoma (STS) of extremities and trunk wall develop disease recurrence after local therapy. Adjuvant chemotherapy with ifosfamide

soft tissue sarcoma
leiomyosarcoma
undifferentiated pleomorphic sarcoma
ifosfamide
cancer chemotherapy
  • 0 views
  • 20 Sep, 2021
  • 2 locations
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

objectives in each of in two cohorts: Cohort A: Hematopoeitic stem cell transplantation (HSCT) eligible patients undergoing second-line salvage chemoimmunotherapy [Rituximab, Ifosfamide, Carboplatin

anthracyclines
etoposide
ejection fraction
cancer chemotherapy
cell transplantation
  • 0 views
  • 23 Feb, 2022
  • 1 location
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide as measured by the overall metabolic response rate after 2 cycles of treatment or at permanent

  • 7 views
  • 27 Feb, 2022
  • 15 locations
A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg Ifosfamide Carboplatin Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

cHL patients. This study evaluates the safety and efficacy of PET-adapted treatment of nivolumab at the fixed dose of 40 mg in combination with ifosfamide, carboplatin, and etoposide (NICE-40) in

refractory hodgkin lymphoma
etoposide
ejection fraction
nivolumab
cell transplantation
  • 0 views
  • 06 Aug, 2021
  • 3 locations